- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | FDA accepts supplemental New Drug Application for Pharming's paediatric immunodeficiency therapy | 4 | PMLiVE | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| Do | Pharming Group-Aktie steigt nach FDA-Zulassung für Leniolisib bei Kindern | 2 | Investing.com Deutsch | ||
| Do | Pharming Group stock rises as FDA approves leniolisib for pediatric APDS | 2 | Investing.com | ||
| Mi | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mi | Pharming shares jump 6% as FDA grants priority review for Joenja in children | 4 | Investing.com | ||
| Mi | FDA Accepts Pharming's SNDA For Leniolisib In Pediatric APDS; Priority Review Granted | 4 | RTTNews | ||
| Mi | Pharming Group N.V.: Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years | 316 | GlobeNewswire (Europe) | If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiencyDecision based... ► Artikel lesen | |
| 10.09. | Pharming Group N.V. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 10.09. | Pharming Group N.V.: Pharming Group promoted to the Euronext AMX index | 191 | GlobeNewswire (Europe) | Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small... ► Artikel lesen | |
| 03.09. | Pharming Group N.V.: Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference | 322 | GlobeNewswire (Europe) | Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th... ► Artikel lesen | |
| 02.09. | Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus | 25 | Zacks | ||
| 02.09. | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 02.09. | Pharming Group names new finance head | 3 | Seeking Alpha | ||
| 02.09. | Pharming Group N.V.: Pharming Group appoints Kenneth Lynard as Chief Financial Officer | 207 | GlobeNewswire (Europe) | Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer... ► Artikel lesen | |
| 20.08. | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | 371 | EQS Group (EN) | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
20.08.2025 / 16:37 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 04.08. | Pharming Group N.V.: Pharming Group to participate in August investor conference | 466 | GlobeNewswire (Europe) | Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conference... ► Artikel lesen | |
| 31.07. | Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M | 9 | Seeking Alpha | ||
| 31.07. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 31.07. | Pharming reports Q2 results | 2 | Seeking Alpha | ||
| 31.07. | Pharming Group N.V.: Pharming Group reports second quarter and first half 2025 financial results and provides business update | 603 | GlobeNewswire (Europe) | Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 16,895 | -0,56 % | Figma, Beam, Intellia: Cathie Wood setzt auf riskante (Bio-)Tech-Aktien | Die bekannte US-Investorin Cathie Wood blieb ihrer Linie auch im August 2025 treu und griff wieder einmal beherzt bei spekulativen Tech- und Biotech-Werten zu. Mit ihrem wichtigsten Fonds, dem ARK Innovation... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,294 | +2,91 % | PacBio Enters Carrier Screening Market With PureTarget Expansion | ||
| CENTOGENE | 0,093 | -0,11 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 4,440 | +2,45 % | Atai Life Sciences files to sell 45.32M common shares by selling shareholders | ||
| BIOMERIEUX | 116,20 | -0,17 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 3,813 | -6,40 % | Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd. | KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals | ||
| GENUS | 28,600 | +2,14 % | Genus - Total Voting Rights | ||
| ANAPTYSBIO | 26,800 | +1,52 % | AnaptysBio, Inc.: Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 | Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,950 | +1,60 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| ABIONYX PHARMA | 3,480 | +1,46 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma: (Paris:ABNX)
Market:... ► Artikel lesen | |
| AKESO | 15,000 | -1,96 % | AKESO (09926): 2025 INTERIM REPORT | ||
| MEIRAGTX | 6,800 | -4,90 % | MeiraGTx Reports Second Quarter 2025 Financial and Operational Results | - Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX)... ► Artikel lesen | |
| MAAT PHARMA | 4,290 | +4,38 % | MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,055 | -14,40 % | Isofol Medical AB: Isofol's clinical study with arfolitixorin reaches another important milestone | GOTHENBURG, Sweden, September 30, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose level in the dose escalating... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,800 (+6,35 %) liegt der Kurs bei 13,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.